Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Schaefer
Werner
W
D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011812:Quinuclidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000069464:Solifenacin Succinate; D009626:Terminology as Topic; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate